Across the recent three months, 10 analysts have shared their insights on Harmony Biosciences (NASDAQ:HRMY), expressing a variety of opinions spanning from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $48.2, a high estimate of $53.00, and a low estimate of $40.00. Surpassing the previous average price target of $42.67, the current average has increased by 12.96%.

Breaking Down Analyst Ratings: A Detailed Examination

A clear picture of Harmony Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of Harmony Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Harmony Biosciences analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Harmony Biosciences: A Closer Look

Understanding the Numbers: Harmony Biosciences's Finances

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Harmony Biosciences displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 31.26%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Harmony Biosciences's net margin excels beyond industry benchmarks, reaching 15.8%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Harmony Biosciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.61%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Harmony Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.35% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Harmony Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.41, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: Simplified

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.